Shantanu Pande¹*, Nihit Mhatre² and Ipsita Dhal³

¹Assistant Professor, Department of Nuclear Medicine, All India Institutes of Medical Sciences, Nagpur, Maharashtra, India
²Senior Resident, Department of Nuclear Medicine, Tata Memorial Hospital, Dr E Borges Marg, Parel East, Mumbai, India
³Assistant Professor, Department of Pathology, Homi Bhabha Cancer Hospital and Mahamana Pandit Madanmohan Malaviya Cancer Centre, Sundar Bagiya, BHU Campus, Varanasi, India

*Corresponding Author: Shantanu Pande, Assistant Professor, Department of Nuclear Medicine, All India Institutes of Medical Sciences, Nagpur, Maharashtra, India.

Received: May 17, 2022; Published: July 15, 2022

Abstract

Objectives: To evaluate role of 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) in assessing bone marrow involvement in rhabdomyosarcoma (RMS) patients, and whether 18F-FDG PET/CT findings render invasive bone marrow biopsy (BMB) unnecessary.

Materials and Methods: This retrospective study included 20 patients (age < 20 years) with biopsy-proven RMS who underwent 18F-FDG PET/CT and BMB for initial staging between August 2018 to December 2020. The 18F-FDG PET/CT scans were evaluated for bone marrow involvement and compared with the BMB results.

Results: The 18F-FDG PET/CT findings and BMBs excluded bone marrow involvement in 19/20 patients. In the remaining patient, 18F-FDG PET/CT suggested metastatic bone marrow involvement, and BMB detected marrow invasion by malignant cells. Thus, for evaluation of bone marrow involvement, 18F-FDG PET/CT showed a specificity and negative predictive value of 100%, suggesting that BMB may be unnecessary.

Conclusions: 18F-FDG PET/CT showed a high specificity and high negative predictive value for detecting bone marrow metastasis in RMS patients, and its use could preclude the need for invasive BMB. However, further studies are required, as our present work had certain limitations.

Keywords: Rhabdomyosarcoma; FDG PETCT; Bone Marrow Biopsy; Pediatrics

References

1. Clark MA., et al. “Soft-tissue sarcomas in adults”. The New England Journal of Medicine 353 (2005): 701-711.
2. Coindre JM., et al. “Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group”. Cancer 91 (2001): 1914-1926.
3. Fletcher CDM., et al. “World Health Organization Classification of Tumors”. Pathology and Genetics of Tumors of Soft Tissue and Bone. IARC Press: Lyon (2002).
4. Ries LAG., et al. “Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995”. NIH Pub. No. 99-4649. Bethesda, MD: National Cancer Institute (1999).
5. West Midlands Cancer Intelligence Unit. “Soft tissue sarcomas: incidence and survival rates in England”. The National Cancer Intelligence Network, 2011 (2014).
6. Hayes-Jordan A and Andrassy R. “Rhabdomyosarcoma in children”. Current Opinion in Pediatrics 21 (2009): 373-378.
7. Meyers PA., et al. “Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high dose methotrexate”. Journal of Clinical Oncology 23 (2005): 2004-2011.
8. Bernstein M., et al. “Ewing’s sarcoma family of tumors: current management”. Oncologist 11 (2006): 503-519.
9. Wexler LH., et al. “Rhabdoyosarcoma”. In: Pizzo PA, Poplack's DG, editors. Principles and Practice of Pediatric Oncology. Philadelphia, PA: Lippincott Williams and Wilkins (2011).
10. Oberlin O., et al. “Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups”. Journal of Clinical Oncology 26 (2008): 2384-2389.
11. Crist W., et al. “The third Intergroup Rhabdomyosarcoma Study”. Journal of Clinical Oncology 13 (1995): 610-630.
12. Koscielniak E., et al. “Results of treatment for soft tissue sarcoma in childhood and adolescence: A final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86”. Journal of Clinical Oncology 17 (1999): 3706-3719.
13. Stevens MC., et al. “Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: Third study of the International Society of Paediatric Oncology-SIOP malignant mesenchymal tumor 89”. Journal of Clinical Oncology 23 (2005): 2618-2628.
14. Krishnan K., et al. “The biology of metastases in pediatric sarcomas”. Cancer Journal 11 (2005): 306-313.
15. Guillerman, RP., et al. “Imaging studies in the diagnosis and management of pediatric malignancies”. In: Pizzo, PA.; Poplack's, DG, editors. Principles and Practice of Pediatric Oncology. Philadelphia, PA: Lippincott Williams and Wilkins (2011).
16. El-kholy E and Rezk M. “18F-FDG PET/CT in Staging Pediatric Rhabdomyosarcoma; Added benefits in comparison to conventional imaging”. Egyptian Journal of Radiology and Nuclear Medicine 18 (2019): 25-39.
17. Federico SM., et al. “Comparison of PET-CT and Conventional Imaging in Staging Pediatric Rhabdomyosarcoma”. Pediatric Blood Cancer 60 (2013): 1128-1134.
18. Bain BJ. “Bone marrow biopsy morbidity: review of 2003”. Journal of Clinical Pathology 58 (2005): 406-408.
19. Newman EN., et al. “An evaluation of [F-18]- fluorodeoxy-D-glucose positron emission tomography, bone scan, and bone marrow aspiration/biopsy as staging investigations in Ewing sarcoma”. Pediatric Blood Cancer 60 (2013): 1113-1117.
20. Kopp LM., et al. “Utility of bone marrow aspiration and biopsy in initial staging of Ewing sarcoma”. Pediatric Blood Cancer 62 (2015): 12-15.
21. Völker T., et al. “Positron Emission Tomography for Staging of Pediatric Sarcoma Patients: Results of a Prospective Multicenter Trial”. Journal of Clinical Oncology 25 (2007): 5435-5441.
22. Eugene T., et al. “¹⁸F-FDG-PET/CT in initial staging and assessment of early response to chemotherapy of pediatric rhabdomyosarcomas”. Nuclear Medicine Communications 33 (2012): 1089-1095.

Citation

Citation: Shantanu Pande., et al. “Can 18F-FDG PET/CT Replace Bone Marrow Biopsy in the Rhabdomyosarcoma Patients?". Acta Scientific Women's Health 4.8 (2022): 57-60.

Copyright

Copyright: © 2022 Shantanu Pande., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.